N-(3-(5-Chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide
| Title | Journal |
|---|---|
| Identification of potent Yes1 kinase inhibitors using a library screening approach. | Bioorganic & medicinal chemistry letters 20130801 |
| Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. | Molecular cancer therapeutics 20121001 |
| Irreversible protein kinase inhibitors: balancing the benefits and risks. | Journal of medicinal chemistry 20120726 |
| NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells. | Biochemical and biophysical research communications 20120713 |
| Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. | Clinical cancer research : an official journal of the American Association for Cancer Research 20120701 |
| Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant. | Journal of medicinal chemistry 20120322 |
| WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. | Laboratory investigation; a journal of technical methods and pathology 20120301 |
| Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. | Nature 20091224 |